- 17 July 2019
- Transport / Logistics Services
Pharmaceutical giant AstraZeneca has committed to convert its entire, 16,000 strong vehicle fleet to electric by 2030.
From a current baseline of 808 electric vehicles AstraZeneca is to operate 120 EVs in the UK (23 per cent of UK fleet); 213 in Spain (35 per cent of Spanish fleet); 245 in France (over 50 per cent of French fleet); and 230 in Scandinavia (over 50 per cent of Scandinavian fleet).
Feeding the electric fleet, the company commits to getting 100% of its energy from renewable sources. This sits at 61% at present.
Katarina Ageborg, EVP, sustainability and chief compliance officer, AstraZeneca, said: “Recognising the link between a healthy environment and human health, we believe that by investing in electric vehicles and emissions-reduction initiatives, we can help reduce the burden of respiratory diseases and other air pollution-related conditions. Environmental stewardship will prevent disease as well as protect the planet for future generations.
As well as shifting its company fleet to EVs the firm is going to install EV charging infrastructure at its site cap parks. It aims to save some 80,000 tonnes of CO2 annually from 2030.
The firm is the first Big Pharma company to join The Climate Group’s EV100 initiative. It is based in the UK but has sites in the US and Sweden.
Helen Clarkson, chief executive of The Climate Group, said: “When a pharmaceutical company says we need to go electric to help everyone breathe clean air, every business with a fleet needs to listen. This is great example of a company addressing the global climate and air pollution crisis. As the first global healthcare company to flip its fleet through EV100, and the 50th large business to do so, AstraZeneca is setting a new benchmark in the drive to electric vehicles.”